Advanced search
Publication Cover
Current Medical Research and Opinion Volume 23, 2007 - Issue 5
Submit an article Journal homepage
61
Views
7
CrossRef citations to date
0
Altmetric
Original Article

A phase I clinical and pharmacokinetic study of tipifarnib in combination with docetaxel in patients with advanced solid malignancies*

Ahmad Awada Jules Bordet Institute, Brussels, BelgiumCorrespondence[email protected]
,
Steven Zhang Johnson & Johnson Pharmaceutical Research and Development, Beerse, Belgium, and Titusville, NJ, USA
,
Thierry Gil Jules Bordet Institute, Brussels, Belgium
,
Dominique de Valeriola Jules Bordet Institute, Brussels, Belgium
,
Yassine Lalami Jules Bordet Institute, Brussels, Belgium
,
Peter De Porre Johnson & Johnson Pharmaceutical Research and Development, Beerse, Belgium, and Titusville, NJ, USA
&
Martine J. Piccart-Gebhart Jules Bordet Institute, Brussels, Belgium
 show all
Pages 991-1003 | Accepted 05 Feb 2007, Published online: 21 Mar 2007

Citations (7)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Nan Soon Wong, Kellen L. Meadows, Lee S. Rosen, Alex A. Adjei, Scott H. Kaufmann, Michael A. Morse, William P. Petros, Yali Zhu, Paul Statkevich, David L. Cutler, Michael L. Meyers & Herbert I. Hurwitz. (2011) A Phase I Multicenter Study of Continuous Oral Administration of Lonafarnib (SCH 66336) and Intravenous Gemcitabine in Patients With Advanced Cancer. Cancer Investigation 29:9, pages 617-625.
Read now
Apostolia Maria Tsimberidou, Chandtip Chandhasin & Razelle Kurzrock. (2010) Farnesyltransferase inhibitors: where are we now?. Expert Opinion on Investigational Drugs 19:12, pages 1569-1580.
Read now

Articles from other publishers (5)

Khalid Jazieh, Julian Molina, Jacob Allred, Jun Yin, Joel Reid, Matthew Goetz, Vun-Sin Lim, Scott H. Kaufmann & Alex Adjei. (2018) A phase I study of the farnesyltransferase inhibitor Tipifarnib in combination with the epidermal growth factor tyrosine kinase inhibitor Erlotinib in patients with advanced solid tumors. Investigational New Drugs 37:2, pages 307-314.
Crossref
Francesco Perri, Roberto Pacelli, Giuseppina Della Vittoria Scarpati, Laura Cella, Mario Giuliano, Francesco Caponigro & Stefano Pepe. (2015) Radioresistance in head and neck squamous cell carcinoma: Biological bases and therapeutic implications. Head & Neck 37:5, pages 763-770.
Crossref
Pauline Gerritsen-van Schieveen & Bernard Royer. (2011) Level of evidence for therapeutic drug monitoring of taxanes. Fundamental & Clinical Pharmacology 25:4, pages 414-424.
Crossref
Pauline Gerritsen-van Schieveen & Bernard Royer. (2010) Niveau de preuve du suivi thérapeutique pharmacologique du docétaxel. Therapies 65:3, pages 201-206.
Crossref
Sarah A. Holstein & Raymond J. Hohl. 2009. Pharmacology and Therapeutics. Pharmacology and Therapeutics 83 90 .

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.